This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

9 Meters Biopharma 미래 성장

Future 기준 확인 2/6

9 Meters Biopharma (는) 각각 연간 41.4% 및 56.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 39.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -185.6% 로 예상됩니다.

주요 정보

41.4%

수익 성장률

39.9%

EPS 성장률

Pharmaceuticals 수익 성장	23.9%
매출 성장률	56.6%
향후 자기자본 수익률	-185.6%
애널리스트 커버리지	Low
마지막 업데이트	30 May 2023

최근 미래 성장 업데이트

Recent updates

9 Meters Biopharma to execute 1-for-20 reverse stock split

Oct 17

9 Meters Biopharma GAAP EPS of -$0.04 in-line

Aug 15

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

Jun 14

9 Meters drug effective in treating rare COVID-19 complication in children

May 26

9 Meters Bio gains 5% on Adage Capital stake disclosure

Dec 29

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

Dec 21

9 Meters Bio launches equity offering

Dec 11

수익 및 매출 성장 예측

NasdaqCM:NMTR - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2025	N/A	-43	N/A	N/A	2
12/31/2024	N/A	-41	N/A	N/A	3
12/31/2023	3	-43	N/A	N/A	4
3/31/2023	N/A	-46	-37	-37	N/A
12/31/2022	N/A	-44	-37	-37	N/A
9/30/2022	N/A	-41	-35	-35	N/A
6/30/2022	N/A	-46	-36	-34	N/A
3/31/2022	N/A	-43	-36	-33	N/A
12/31/2021	N/A	-37	-32	-29	N/A
9/30/2021	N/A	-32	-30	-28	N/A
6/30/2021	N/A	-27	-24	-24	N/A
3/31/2021	N/A	-63	-26	-23	N/A
12/31/2020	N/A	-61	-23	-19	N/A
9/30/2020	N/A	-65	-19	-16	N/A
6/30/2020	N/A	-66	-19	-16	N/A
3/31/2020	N/A	-26	-16	-16	N/A
12/31/2019	N/A	-27	-18	-18	N/A
9/30/2019	N/A	-22	-17	-17	N/A
6/30/2019	N/A	-14	-17	-17	N/A
3/31/2019	N/A	-14	-12	-12	N/A
12/31/2018	N/A	-24	-15	-15	N/A
9/30/2018	N/A	-22	-15	-15	N/A
6/30/2018	N/A	-24	-12	-12	N/A
3/31/2018	N/A	-23	-11	-11	N/A
12/31/2017	N/A	-12	-5	-5	N/A
9/30/2017	N/A	-11	-4	-4	N/A

애널리스트 미래 성장 예측

수입 대 저축률: NMTR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: NMTR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: NMTR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: NMTR 의 수익(연간 56.6% ) US 시장( 8.9% 보다 빠르게 성장할 것으로 예상됩니다. 8.9% 연간).

고성장 수익: NMTR 의 수익(연간 56.6% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: NMTR (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

This company listing is no longer active

9 Meters Biopharma 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Price target increased by 18% to US$39.20

Price target decreased by 15% to US$33.12

Price target decreased to US$57.00

Recent updates

9 Meters Biopharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Rule

9 Meters Biopharma, Inc. Appoints Bethany Sensenig as Interim CEO

9 Meters Biopharma, Inc. Provides Clinical Update on Vurolenatide in Patients with Short Bowel Syndrome

Price target decreased by 43% to US$10.25

Consensus EPS estimates fall by 43%

Price target decreased by 32% to US$22.68

Price target increased by 18% to US$39.20

Price target decreased by 15% to US$33.12

9 Meters Biopharma, Inc. Announces Phase 3 Study of Vurolenatide in Short Bowel Syndrome

High number of new and inexperienced directors

Price target decreased to US$57.00

9 Meters Biopharma to execute 1-for-20 reverse stock split

Price target increased to US$3.40

9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA for Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma GAAP EPS of -$0.04 in-line

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

9 Meters Biopharma, Inc. announced that it expects to receive $70 million in funding

Price target decreased to US$3.33

Independent Chairman recently bought US$50k worth of stock

9 Meters Biopharma, Inc., Annual General Meeting, Jun 22, 2022

High number of new and inexperienced directors

President recently bought US$56k worth of stock

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Price target decreased to US$4.33

President recently bought US$53k worth of stock

President recently bought US$53k worth of stock

Independent Chairman recently bought US$100k worth of stock

Director Sandeep Laumas has left the company

9 Meters Biopharma, Inc. Announces Initiation of Phase 2 Vibrant Study of Vurolenatide for Short Bowel Syndrome

9 meters launches Phase 2 VIBRANT study of vurolenatide for short bowel syndrome

9 Meters Biopharma, Inc. Announces Publication in Journal of Clinical Investigation Describing Successful Use of Larazotide for Treating Multisystem Inflammatory Syndrome in Children Resulting from Covid-19 Infection

9 Meters drug effective in treating rare COVID-19 complication in children

9 Meters Biopharma, Inc. Receives USAN Approval to Use the Designated Nonproprietary Name Vurolenatide for Its Long-Acting GLP-1 Agonist for Short Bowel Syndrome

Forecast to breakeven in 2024

9 Meters Biopharma Hosting Key Opinion Leader Webinar on Short Bowel Syndrome and NM-002 Program Update

9 Meters Biopharma Inc Appoints Michael Rice as Board of Director

9 Meters Biopharma, Inc. Announces the Resignation of Nissim Darvish as Director

Independent Director has left the company

New 90-day high: US$1.50

New 90-day high: US$1.37

9 Meters Bio gains 5% on Adage Capital stake disclosure

9 Meters Biopharma slumps, continues evaluation of Larazotide for COVID-19 respiratory complications

9 Meters Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $30.000001 million.

9 Meters Bio launches equity offering

9 Meters Biopharma Announces Positive Preclinical Data for NM-102, a Gut Microbiome Modulator in an Immune Checkpoint Inhibitor Failure Model

New 90-day high: US$0.89

New 90-day high: US$0.85

Independent Chairman recently bought US$96k worth of stock

Independent Chairman recently bought US$56k worth of stock

New 90-day low - US$0.47

Innovate Biopharmaceuticals, Inc. (NasdaqCM:INNT) completed the acquisition of RDD Pharma, Ltd. from OrbiMed Israel Partners managed by OrbiMed Advisors, L.L.C. and others.

9 Meters Biopharma, Inc.(NasdaqCM:NMTR) dropped from Russell Microcap Index

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견